#### Check for updates

#### **OPEN ACCESS**

EDITED BY Vincenzo Davide Palumbo, Euro-Mediterranean Institute of Science and Technology (IEMEST), Italy

REVIEWED BY Mudasir Rashid, Howard University Hospital, United States Zhengrui Li, Shanghai Jiao Tong University, China Yin Li, Tianjin University, China Zhongyue Yang, Stanford University, United States

\*CORRESPONDENCE Xi Zhou ⊠ zhoux@njucm.edu.cn

RECEIVED 22 May 2024 ACCEPTED 10 October 2024 PUBLISHED 11 November 2024

#### CITATION

Sun X, Zhang S and Zhou X (2024) A causal association between obesity and constipation: a two-sample bidirectional Mendelian randomization study and meta-analysis. *Front. Nutr.* 11:1430280. doi: 10.3389/fnut.2024.1430280

#### COPYRIGHT

© 2024 Sun, Zhang and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# A causal association between obesity and constipation: a two-sample bidirectional Mendelian randomization study and meta-analysis

# Xian Sun<sup>1</sup>, Shuoqiu Zhang<sup>2</sup> and Xi Zhou<sup>1\*</sup>

<sup>1</sup>School of Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China, <sup>2</sup>Jiangsu Research Center for Chinese Medicine Development, Nanjing, China

**Objective:** Observational studies suggest a potential link between obesity and constipation, but existing results are conflicting. Therefore, we conducted a Mendelian randomization (MR) study and meta-analysis to assess the causal relationship between obesity and the risk of constipation.

**Methods:** In this study, independent genetic variants closely related to constipation were acquired from a genome-wide association study (GWAS) to analyze the relationship between genetically predisposed obesity and the risk of constipation. Waist circumference (WC), hip circumference (HC), waist-to-hip ratio (WHR), and body mass index (BMI) were collected from the GWAS. Then, the causal relationship between constipation and obesity was explored using a two-sample MR study in both directions. The robustness of the results was evaluated using sensitivity analysis. Furthermore, a systemic review and meta-analysis were performed to calculate relative risks (RRs) with corresponding 95% confidence intervals (95% CIs). Subgroup analyses stratified by age and obesity degree were completed. To evaluate whether the current studies were affected by unmeasured confounders, *E*-values of each study were determined.

**Results:** In MR analysis, the incidence of constipation increased with the increase in BMI [inverse variance-weighted (IVW) odds ratio (OR) = 1.138 (1.029, 1.260), p = 0.012]. In addition, constipation was impacted by WC [IVW OR = 1.220 (1.061, 1.402), p = 0.005]. However, there was no evidence that WHR [IVW OR = 1.833 (0.826, 4.065), p = 0.136] or HC [IVW OR = 0.949, (0.836, 1.077), p = 0.415] has a causal effect on constipation. In reverse MR analysis, there was no evidence supporting the causality between constipation and obesity [BMI IVW OR = 1.010 (0.998, 1.022), p = 0.089; WHR IVW OR = 1.000 (0.946, 1.057), p = 0.994; WC IVW OR = 1.008 (0.995, 1.022), p = 0.217; HC IVW OR = 0.996 (0.982, 1.011), p = 0.626]. In the meta-analysis, 14 eligible articles were included, involving 43,488 subjects. According to the results of the meta-analysis, the risk of obesity and overweight significantly increased the risk of constipation [RR = 1.145 (0.952, 1.376)]. This was consistent with the MR analysis results. Moreover, overweight and obesity were significantly related to a higher constipation risk among children [overweight RR = 1.112 (0.943, 1.312); obesity RR = 1.407 (1.282, 1.544)]. Additionally, overweight in adults could decrease the risk of constipation [RR = 0.940 (0.827, 1.068)]. Nevertheless, no significant association was observed between obesity in adults and the risk of constipation [RR = 1.000 (0.768, 1.303)]. Sensitivity analysis revealed the robustness of our findings.

**Conclusion:** In this combined MR study and meta-analysis, obesity is associated with an increased risk of constipation. The MR analysis demonstrates the causal relationship between genetically predisposed obesity and the risk of constipation. More research is required to investigate the potential correlation between obesity and the risk of constipation and associated mechanisms.

KEYWORDS

obesity, constipation, Mendelian randomization, meta-analysis, causal association

# **1** Introduction

Constipation, a common gastrointestinal disorder globally, is reported to influence 4 and 10.2% of men and women, respectively (1). This effect includes physical and social functioning and mental health of patients (2, 3). The cost of medication for constipation patients is very expensive. In the United States, the annual medical expenses of constipation treatment reach US\$230 million (4). Constipation is associated with many factors. As reported in one cross-sectional study in Turkey, physical inactivity, decreased water/ fiber consumption, aging, female sex, and obesity are related to the higher constipation risk (5).

Obesity is a health problem worldwide. Globally, the incidence of obesity and its associated disorders exhibits an increasing trend, and there are currently over 2 billion overweight people (6). In addition, its morbidity and mortality are widely investigated in different organ systems, such as its gastrointestinal presentations on the gallbladder, liver, and upper gastrointestinal motility (7, 8).

The association between obesity and constipation has attracted significant attention, with increasing evidence indicating a complex interaction between the two. Constipation and obesity have not been associated statistically significantly in children (9), while some studies suggest that obesity might contribute to adult constipation (10). However, several critical gaps and unresolved issues need to be further investigated. Current research predominantly concentrates on a unidirectional approach, assessing how obesity increases the risk of constipation (11). There has been limited exploration of how constipation may influence obesity in return and potentially exacerbate it. This unidirectional design may overlook potential bidirectional causal relationships, causing an incomplete understanding of the interactive mechanisms between the two conditions. For example, a study performed by Costa et al. (12) indicated a significant association between obesity and constipation through data analysis but could not determine whether this relationship was causal or driven by other factors. Obesity and constipation are influenced by many factors, including age, sex, and genetic background, which vary across different populations. Sample heterogeneity in various studies has contributed to inconsistent findings.

Bidirectional Mendelian randomization uses genetic variants as instrumental variables, leveraging the random allocation of genetic variants to mimic randomized controlled trials. This approach effectively controls confounders and helps uncover the causal relationship between obesity and constipation, clarifying whether obesity directly leads to constipation or whether constipation influences obesity in return. The application of bidirectional MR has greatly benefited from advances in large-scale genome-wide association studies, providing high-quality genetic instruments for MR analyses. Using the latest statistical methods, the precision and reliability of the results can be improved, enhancing the clinical translation potential of this approach. Different from traditional unidirectional MR, bidirectional MR not only assesses the causal effect of obesity on constipation but also explores the reverse effect of constipation on obesity. Moreover, this innovative bidirectional analysis offers a comprehensive view of disease interaction pathways, providing a more complete scientific basis for developing clinical treatment and prevention strategies. Moreover, the combination of MR analysis and meta-analysis can significantly enhance the persuasive of results. Therefore, the present MR study and metaanalysis were performed to investigate the causal association between obesity and the risk of constipation.

# 2 Materials and methods

## 2.1 Mendelian randomization analysis

## 2.1.1 Study design

This two-sample MR analysis used several single nucleotide polymorphisms (SNPs) representing genetic variation. There are three assumptions to be satisfied (Figure 1): (1) instrumental variables (IVs) are associated with exposure; (2) IVs are independent of other confounders; and (3) genetic variation influences outcomes solely through exposure (13). In addition, a bidirectional causal association between obesity and constipation was evaluated using MR analysis.

## 2.1.2 Data sources

In adults, overweight was deemed as body mass index (BMI)  $\geq$  25 kg/m<sup>2</sup>, while obesity was deemed as BMI  $\geq$  30 kg/m<sup>2</sup> based on the criteria of the World Health Organization (WHO). In adolescents, as defined by the growth charts of the Centers for Disease Control and Prevention, overweight and obesity were classified as the 85th-95th and≥95th percentiles in age- and sex-specific BMI distributions, respectively (14). BMI has been the common method used globally for measuring body fat and thinness degree. The general obesity index is calculated according to the BMI [total mass (kg)/height square (m<sup>2</sup>)]. WHR [WC (cm)/HC (cm)] and IBM-adjusted WHR are considered the central obesity indices. We searched BMI (n = 532,396), WHR (n=142,762), WC (n=462,166), and HC (n=336,601) as exposure factors in European ancestry, which were derived from GWASs, such as the IEU open GWAS, and the GWAS Catalog, and obtained qualified datasets. Additionally, BMI (n = 158,284) and HC (n=92,615) GWAS summary data from East Asian ancestry could be acquired using the same method.

Single nucleotide polymorphisms that were obtained from the GWAS dataset show significance at the whole genome level



 $(p < 5 \times 10^{-8})$  and were selected for this study. Ethical approval was waived due to the use of data from public databases.

In total, 451,567 subjects of European ancestry were enrolled in our constipation analysis, including 4,781 participants with constipation and 44,6,786 healthy controls. A total of 176,629 subjects of East Asian ancestry were included, consisting of 397 participants with constipation and 176,232 healthy controls. Supplementary Table S1 presents the exposure and outcome features. There existed no overlapping population in GWASs between outcomes and exposures.

## 2.1.3 SNP screening

Single nucleotide polymorphisms are frequently seen as genetic variants in human beings, which can serve as IVs to replace traits in MR analysis (15, 16). Appropriate SNPs were selected from the exposure-related GWASs based on the following criteria: (1) a genome-wide significance *p*-value of  $<5 \times 10^{-8}$ ; if sufficient SNPs were not available, a relaxed threshold of  $5 \times 10^{-6}$  was used. (2) *F*-statistics >10. (3) SNPs in linkage disequilibrium (LD) were eliminated using a clumping window of 10 MB and  $r^2$  value <0.01. (4) PhenoScanner V2 was applied to eliminate SNPs associated with outcomes and potential confounders.

## 2.1.4 Two-sample Mendelian randomization

This MR study operated in two opposite directions, with one predicting the causal impact of obesity on constipation, whereas the other predicted the effect of constipation on obesity.

In this study, the inverse variance weighted (IVW) method was used as the main MR method as it is the earliest and the most commonly used method in MR analysis (17). Meanwhile, four other MR methods, namely, weighted median, weighted mode, simple mode, and MR-Egger were applied. Among them, the IVW method conducts MR on the impact of SNP exposure on the outcome, with adjustment for heterogeneity. By contrast, the weighted median determines the median causal estimate, the weighted mode determines the mode, and the simple mode predicts causal association with no weights, while the MR-Egger addresses the pleiotropy problem. The integration of these approaches can strengthen the robustness of the results and provide various insights. In IVW analysis, valid IVs are assumed, and deviations influence the precision. These methods contribute to comprehensively viewing the causality, considering different assumptions and biases. In this study, the MR study was carried out using the TwoSampleMR package (version: 0.5.8) and R Software (version: 4.3.2).

### 2.1.5 Heterogeneity and sensitivity analyses

A fixed-effect IVW approach was used for primary analysis to analyze the overall effects without heterogeneity (18). Nevertheless, a random-effects model IVW approach was used when heterogeneity was determined between causal estimates of genetic variances. Cochran's *Q* statistic was calculated in the MR study to predict the presence/absence of heterogeneity, with a *p* value <0.05 indicating the existence of heterogeneity in the MR analysis. The fixed-effects IVW method was used when the *p*-value was >0.05 in Cochran's *Q* statistic, while the random-effects IVW approach was utilized when the *p* value was <0.05 (19). *I*<sup>2</sup> statistic was determined to explore the heterogeneity level (20).

Sensitivity analysis was carried out to examine whether the MR results were robust against possible deviation from three major assumptions. A *p* value of MR-Egger regression's intercept was used to assess horizontal pleiotropy. If pleiotropy exists (p < 0.05), outliers of SNPs were removed. A leave-one-out test was used to estimate the potential pleiotropy effect of single SNPs.

# 2.2 Meta-analysis

## 2.2.1 Study retrieval

The Cochrane Library, Web of Science, PubMed, and Embase databases were searched using the string "((overweight) OR obesity) AND constipation" from inception to 1 February 2024 to identify relevant studies. Supplementary Table S5 displays search strings used for identifying studies from the PubMed, Cochrane Library, Embase, and Web of Science databases. Figure 2 presents the study retrieval process. In addition, this study also manually searched references in



eligible articles to prevent the omission of qualified articles. We would contact with original authors to obtain further information.

Publications concerning constipation risk in obese patients satisfying the criteria mentioned below were enrolled: (1) cohort or case–control or cross-sectional studies; (2) articles assessing the association between obesity and constipation risk; and (3) articles with available or calculable relative risk (RR) or odds ratio (OR) and 95% CIs.

The following publications were eliminated: (1) case reports; (2) articles from referral centers; (3) non-English publications, duplicates, or conference abstracts with no follow-up publication; and (4) studies with unavailable data to calculate effect size for this meta-analysis.

## 2.2.2 Data extraction and quality assessment

Data were extracted and validated by two authors (Shuoqiu Zhang and Xian Sun), with disputes resolved through discussions or the opinion of a third author (Xi Zhou). The data extracted from each included publication consisted of the last name of first author, publication year, study region/country, participant number (cases and controls/non-cases/cohort size), study quality, and study design. For at-risk cases and non-at-risk cases/participants, their data were adjusted for different exposure categories and covariates prior to later analysis, if necessary.

## 2.2.3 Bias risk evaluation

Bias risk was assessed by two authors (Shuoqiu Zhang, and Xian Sun) independently according to the description in the Cochrane Handbook, and any dispute between them was settled through discussion. Randomization generation, allocation concealment, blinding, patient proportion completing follow-up, intention-to-treat analysis, and selective outcome reporting were recorded.

## 2.2.4 Quality assessment

This study employed the Newcastle–Ottawa Quality Assessment Scale to assess cohort study and case–control study quality. Any dispute was settled through discussion. The overall scores of 0.0–6.0 and 6.5–9.0 indicated low- and high-quality studies, respectively (21). Cross-sectional studies were evaluated using the 11-item checklist of the Agency for Healthcare Research and Quality (AHRQ) (22), with 0–3, 4–7, and 8–11 points suggesting low, moderate, and high-quality studies, respectively (23). Study quality was evaluated independently by two researchers (Shuoqiu Zhang and Xian Sun).

## 2.2.5 Statistical analysis

The random-effects model was used in data pooling (24), aiming to provide the conserved estimate of the impact of overweight or obesity, and inter-study heterogeneity was allowed. This study used RRs as the risk estimate. Owing to the low absolute constipation risk in human beings, we deemed ORs as RRs (25, 26). Both Cochran's Q test and  $I^2$ -statistic were used for assessing the possible heterogeneity of our enrolled articles (20, 27).  $I^2 > 50\%$  and p < 0.05 represented heterogeneity in results (28), and thus, a random-effects model should be used; or else, a fixed-effects model would be used. In sensitivity analysis, one study was eliminated each time to evaluate its impact on the pooled risk estimates. Subgroup analyses stratified by child and adult populations were performed. Publication bias was assessed by Egger (29) linear regression. p < 0.05 stood for statistical significance. R Software (Version: 4.3.2) and meta package (Version: 6.5-0) were used in statistical analysis.

### 2.2.6 Ethical statement

This meta-analysis was carried out on the basis of prior publications, without any original data. Therefore, neither patient consent nor ethical approval was needed.

# **3** Results

# 3.1 Mendelian randomization analysis

## 3.1.1 Causal effects of obesity on constipation

The TwoSampleMR package in R was used for the MR analysis, with constipation as the outcome variable and BMI, WHR, WC, and HC as the exposure variables. The overall forest diagram of the analysis results was presented as follows, focusing on the IVW algorithm. We removed confounding factors rs12765337 and rs6702519, which were associated with lifestyles, including drinking, smoking, and stress, as they might simultaneously influence the occurrence of obesity and constipation.

At first, we performed an MR analysis on the European population. As WHR had too few SNPs in common with constipation after *p* value filtering (only two), only the IVW model was used, and there were five models for other indicators. Clearly, BMI and WC were positively related to constipation risk, and the result was significant (p < 0.05). Although HC was negatively related to constipation risk, WHR was positively associated with constipation risk, while the results were not significant (p > 0.05) (Figure 3A).

Impact of BMI on constipation: In total, 898 independent genome-wide significant SNPs were obtained from GWAS. The SNPs used for the MR study were strong IVs, with each of them having an *F*-statistic >10. In the *F*-statistic, the precision and magnitude of the effect of SNP on BMI were considered. F-statistics of the enrolled individuals were 27-1396. In IVW analysis, BMI was causally related to constipation risk [OR=1.138 (1.029, 1.260); p=0.012] (Supplementary Table S2; Supplementary Figures S1A–C).

Impact of WHR on constipation: The GWAS obtained two independent genome-wide significant SNPs. The SNPs used for the MR study were "strong" IVs, and all of them had *F*-statistics >10. In the *F*-statistic, the precision and magnitude of the effect of SNP on WHR were considered. The IVW analysis did not detect the causal association (Supplementary Table S2; Supplementary Figures S4A–C). However, limited by SNP number, causal effects between WHR and constipation need more experiments.

Impact of WC on constipation: We obtained 570 independent SNPs with genome-wide significance from GWAS. The SNPs used for the MR study were "strong" IVs, and all of them had F-statistics >10. In the F-statistic, the precision and magnitude of the effect of SNP on WC were considered. The IVW method identified a potential causal association of WC with constipation risk [OR = 1.220 (1.061, 1.402); p = 0.005] (Supplementary Table S2; Supplementary Figures S3A–C).

Impact of HC on constipation: We acquired 416 independent SNPs with genome-wide significance from GWAS. The SNPs used for the MR study were "strong" IVs, and all of them had *F*-statistics >10. In the *F*-statistic, the magnitude of the effect of SNP on HC and precision was considered. Moreover, no causal association was identified by IVW analysis (Supplementary Table S2; Supplementary Figures S2A–C).

Because the above analyses were all conducted in the European population, we sincerely aim to replicate this analysis in other populations. However, it is regrettable that we just found East Asian GWAS data for MR analysis. When compared with the European population, the result showed significant differences that BMI [OR = 1.1408 (0.613, 2.123); p = 0.677] and HC [OR = 1.306 (0.675, 2.526); p = 0.428] were not associated with constipation (Figure 3C). Another result in the Asian population can be found in Supplementary Table S4 and Supplementary Figures S9A–C, S10A–C.

## 3.1.2 Causal effects of constipation on obesity

The same as the causal effects of obesity and constipation, in this sector, we also used R language to perform MR analysis, with BMI, WHR, WC, and HC as the outcome variables and constipation as the exposure variable. Due to the small amount of data, the threshold of the *p* value was set to  $5 \times 10^{-6}$  (30). It can be found that all the results of reverse MR were not significant (*p*>0.05); that is, constipation did not cause significant changes in obesity-related indicators (Figure 3B).

#### 3.1.2.1 Impact of constipation on BMI

There were 10 independent SNPs with genome-wide significance obtained from GWAS. The SNPs utilized for the MR study were "strong" IVs whose *F*-statistics >10. In the *F*-statistic, the precision and magnitude of the effect of SNP on constipation were explored. *F*-statistics of individuals were 21–27. Using the IVW method, constipation was not causally related to BMI risk [OR=1.010 (0.998, 1.022); p=0.089] (Supplementary Table S3; Supplementary Figures S5A–C).

#### 3.1.2.2 Impact of constipation on WHR

We obtained 11 independent SNPs with genome-wide significance from GWAS. The SNPs used for the MR study were "strong" IVs with F-statistics >10. In the F-statistic, the precision and magnitude of the effect of SNP on WHR were analyzed. The IVW analysis exhibited no causal association between constipation and WHR risk (Supplementary Table S3; Supplementary Figures S8A–C).

A exposure	outcome	nSNP	method							Odds Ratio (95% CI)	p.value
BMI	Constipation	877	MR Egger	⊢●	Ţ					0.94(0.69-1.30)	7.24e-01
		877	Weighted median		⊢♠⊣					1.19(1.01-1.39)	3.61e-02
		877	Weighted mode	μ	<b>.</b>					1.14(0.70-1.86)	6.06e-01
		877	Simple mode	<b>I</b>	<b></b>	——				1.14(0.60-2.16)	6.94e-01
		877	IVW (MRE)		<b>I</b>					1.16(1.05-1.29)	3.96e-03
WHR	Constipation	2	IVW (FE)	F		<b>—</b>					1.36e-01
WC	Constipation	549	MR Egger	<b>—</b>						0.94(0.62-1.43)	7.72e-01
		549	Weighted median	H						1.21(0.96-1.50)	9.99e-02
		549	Weighted mode	<b>—</b>						0.96(0.57-1.63)	8.94e-01
		549	Simple mode	<b>I</b>						1.45(0.63-3.36)	3.83e-01
		549	IVW (FE)		⊢♠⊣					1.22(1.07-1.40)	3.85e-03
HC	Constipation	410	MR Egger	<b>—</b>						0.93(0.63-1.36)	6.99e-01
		410	Weighted median	н	н					1.00(0.83-1.20)	9.91e-01
		410	Weighted mode	<b></b>	•	—				1.23(0.74-2.05)	4.23e-01
		410	Simple mode	⊢	-					1.26(0.65-2.44)	4.91e-01
		410	IVW (MRE)	М	н					0.95(0.84-1.08)	4.15e-01
			и О.		1 1.5	l 2 Odds	2.5 Ratio	3	3.5	4	

#### 3.1.2.3 Impact of constipation on WC

There were 10 independent SNPs with genome-wide significance acquired from constipation GWAS. The SNPs used for the MR study were "strong" IVs whose *F*-statistics were > 10. In the *F*-statistic, the precision and magnitude of the effect of SNP on WC were examined. The IVW analysis did not show any causal correlation between constipation and WC risk (Supplementary Table S3; Supplementary Figures S7A–C).

## 3.1.2.4 Impact of constipation on HC

This study acquired 10 independent SNPs with genome-wide significance from the GWAS. The SNPs utilized for the MR study were "strong" IVs whose *F*-statistics were > 10. In the *F*-statistic, the precision and magnitude of the effect of SNP on HC were explored. The IVW analysis did not exhibit any causal association between constipation and HC risk (Supplementary Table S3; Supplementary Figures S6A–C).

## 3.1.3 Sensitivity and heterogeneity analyses

Supplementary Tables S2–S4 display more detailed sensitivity analysis results. Supplementary Figures S1B–S10B presents the leaveone-out plot. Supplementary Figures S1A–S10A exhibits the funnel plot. Some MR analyses revealed significant heterogeneity (pvalue<0.05). We used random-effects IVW to eliminate this heterogeneity as much as possible. The absence of pleiotropic effects was confirmed in all MR analyses (p\_pleiotropy>0.05).

# 3.2 Meta-analysis

### 3.2.1 Publication screening

A total of 2,228 potential publications were obtained from primary retrieval. Among them, 1,427 were removed by title and abstract reading. Full texts of the rest of the 481 publications were

B exposure	outcome	nSNP	method					Odds Ratio (95% CI)	p.value
Constipation	BMI	10	MR Egger	F	<b>•</b> 1			1.01(0.99-1.04)	2.45e-01
		10	Weighted median		<b>•</b> -1			1.01(1.00-1.03)	1.22e-01
		10	Weighted mode	F	<b> </b>			1.01(0.99-1.04)	4.03e-01
		10	Simple mode	F				1.01(0.99-1.04)	4.08e-01
		10	IVW (FE)		<b>•</b>			1.01(1.00-1.02)	8.93e-02
Constipation	WHR	11	MR Egger	H				1.04(0.94-1.15)	4.40e-01
		11	Weighted median	F				1.03(0.96-1.11)	4.11e-01
		11	Weighted mode	μ				1.04(0.94-1.15)	4.43e-01
		11	Simple mode	F			1	1.04(0.92-1.17)	5.52e-01
		11	IVW (FE)	<b>н</b>	·			1.00(0.95-1.06)	9.94e-01
Constipation	WC	10	MR Egger	<b>⊢</b>				1.01(0.98-1.03)	6.53e-01
		10	Weighted median	F	<b>•</b> ••			1.01(0.99-1.02)	2.82e-01
		10	Weighted mode	F				1.01(0.99-1.03)	4.38e-01
		10	Simple mode	F	<b> </b>			1.01(0.99-1.04)	4.17e-01
		10	IVW (FE)		<b>•</b>			1.01(1.00-1.02)	1.41e-01
Constipation	HC	10	MR Egger	⊢♠				0.99(0.97-1.02)	6.74e-01
		10	Weighted median	H				1.00(0.98-1.02)	7.74e-01
		10	Weighted mode	F	<b>•</b>			1.01(0.97-1.04)	7.28e-01
		10	Simple mode	F	<b> </b>			1.01(0.97-1.04)	7.41e-01
		10	IVW (FE)	H	H			1.00(0.98-1.01)	6.26e-01
							_		
			0.9	0.95	1 1.05 Odds Ratio	1 1.1	ı 1.15		
URE 3 (Continued									

read. Finally, 14 publications were obtained for the final meta-analysis (Supplementary Figure S5).

### 3.2.2 Publication features

A total of 14 publications were included in this meta-analysis, comprising 14 datasets (n = 43,488) and published between 1990 and 2024 (10, 11, 31–41). Supplementary Table S5 presents the main characteristics of all those 14 publications. There were 1,790 children and adolescents in the studies used for this meta-analysis.

The studies were carried out in different regions, including five in North America, one in Europe, one in Oceania, five in Asia, and two in South America. The constipation patient numbers were 6–5,781. Supplementary Table S5 exhibits the study quality score rated by the nine-star NOS or AHRQ system. Therefore, five publications (12, 33, 34, 37, 40) had seven points, seven (10, 11, 31, 32, 36, 38, 41) had eight points, and two (35, 39) had nine points. Following quality assessment criteria, all publications in this meta-analysis had moderate or high quality.

# 3.2.3 Meta-analysis between overweight, obesity, and constipation

The Egger test was used to analyze the possible publication bias in our included studies. Meanwhile, a funnel plot was drawn to evaluate the publication bias risk, which revealed obvious publication bias in one study. Thus, the study performed by Olaru et al. (32) was excluded from our analysis. The rest studies had low bias risk (Supplementary Figure S11).

There were 10 studies (10–12, 31, 33, 35, 37–40) mentioning risk estimates regarding overweight and obesity and constipation risk. Due to the significant heterogeneity ( $I^2 = 90\%$ , p < 0.01; Figure 4), a random-effects model was adopted for this meta-analysis, and a



population. (B) Causal effects of constipation on BMI, HC, WC, and WHR in a European population. (C) Causal effects of BMI, HC, WC, and WHR on constipation in an East Asian population. MR-Egger, weighted median, inverse variance weighted, simple mode, and weighted mode estimates of Mendelian randomization (MR) are summarized. CI, Confidence interval; nSNP, Number of single nucleotide polymorphism; OR, Odds ratio; BMI, Body mass index; HC, Hip circumference; WC, Waist circumference; WHR, Waist-to-hip ratio.

higher constipation risk was detected (RR: 1.145; 95% CI: 0.952-1.376).

From Figure 4, subgroup analysis was employed to analyze factors related to constipation risk in children compared with adult groups. Significant heterogeneity was not detected ( $I^2 = 10\%$ , p = 0.35). Therefore, a common-effect model was used for meta-analysis. As a result, there was a higher constipation risk (RR: 1.172; 95% CI: 1.034–1.327). Nevertheless, due to the obvious heterogeneity ( $I^2 = 95\%$ , p < 0.01) among the adult group, a random-effects model was used for meta-analysis, and a higher constipation risk was detected (RR: 1.101; 95% CI: 0.789–1.536).

# 3.2.4 Meta-analysis between overweight and constipation

Egger test was carried out to evaluate the possible publication bias of the included publications, revealing no obvious publication bias (p=0.4497). Moreover, a funnel plot was drawn to evaluate the publication bias risk (Supplementary Figure 5), and no obvious publication bias was found.

There were eight studies (10, 11, 31, 33, 37–40) reporting estimates of overweight with constipation risk. An obvious heterogeneity was determined ( $I^2 = 58\%$ , p = 0.02; Supplementary Figure S12). Thus, a random-effects model was used for meta-analysis, exhibiting a decreased constipation risk (RR: 0.985; 95% CI: 0.884–1.097).

As shown in Figure 5, subgroup analysis was performed to analyze the factors related to constipation risk in Children compared with adult groups. Significant heterogeneity was not detected ( $I^2 = 0\%$ , p = 0.50), and thus, we utilized the common-effect model for metaanalysis and determined a higher constipation risk (RR: 1.112; 95% CI: 0.943–1.312). Nevertheless, owing to the obvious heterogeneity ( $I^2$  = 67%, p = 0.02) in the adult group, a random-effects model was used for meta-analysis, discovering a decreased constipation risk (RR: 0.940; 95% CI: 0.827–1.068).

# 3.2.5 Meta-analysis between obesity and constipation

Egger test was employed to evaluate the possible publication bias across our included publications. Meanwhile, a funnel plot was utilized to evaluate the publication bias risk, suggesting obvious publication bias in one study. Thus, the study performed by Olaru et al. (32) was excluded from our analysis. The rest publications had a low risk of bias (Supplementary Figure S13).

There were 10 studies (10–12, 31, 33, 36–39, 41) reporting estimates of obesity with constipation risk. Due to the obvious heterogeneity ( $I^2 = 88\%$ , p < 0.01), this study utilized a random-effects model for meta-analysis and found a higher constipation risk (RR: 1.186; 95% CI: 0.989–1.420).

As presented in Figure 6, subgroup analysis was performed to examine factors related to constipation risk in Children compared with adult groups. Due to the absence of obvious heterogeneity ( $l^2 = 44\%$ , p = 0.11), the common-effect model was used for metaanalysis and found a higher constipation risk (RR: 1.407; 95% CI: 1.282–1.544). Nevertheless, considering the significant heterogeneity ( $l^2 = 91\%$ , p < 0.01) among the adult group, this study utilized a

	Exper	imental		Control				Weight	Weight
tudy	Events	Total	Events	Total	Risk Ratio	RR	95%-CI	(common)	(random)
ge = Children					1! :				
eitelbaum JE 2009	82	274	114	483	<u>↓ · ∎</u>	1.268	[0.995; 1.615]	4.8%	9.9%
oppen IJ 2016	99	730	270	2090		1.050	[0.847; 1.301]	6.2%	10.3%
hang SH 2013	19	29	100	172	— <del>[] *</del>	1.127	[0.841; 1.510]	3.3%	9.2%
osta 2011	28	144	168	933		1.080	[0.754; 1.547]	2.2%	8.2%
hatak UP 2014	44	192	36	258		1.642	[1.102; 2.447]	1.8%	7.7%
ommon effect model		1369		3936		1.172	[1.034; 1.327]	18.3%	
andom effects model						1.172	[1.034; 1.327]		45.3%
eterogeneity: $I^2 = 10\%$ , $\tau^2 = <$	: 0.0001, p	= 0.35							
ge = Adult ourhoseingholi MA 2009	548	1389	468	1158		0.976	[0.887; 1.074]	31.0%	11.6%
ong Y 2024	682	10022	370	4026		0.740	[0.656; 0.836]	19.3%	11.4%
udish BI 2009	897	11383	343	5028		1.155	[1.025; 1.302]	19.7%	11.4%
alley NJ 2004	75	387	109	537		0.955	[0.734; 1.242]	4.1%	9.6%
elgado-Aros S 2004	439	1287	103	620	!: <u>-</u>	2.053	[1.695; 2.488]	7.7%	10.6%
ommon effect model		24468		11369		1.020	[0.962; 1.082]	81.7%	
andom effects model						1.101	[0.789; 1.536]		54.7%
eterogeneity: $I^2 = 95\%$ , $\tau^2 = 0$	0.1370, <i>p</i> <	0.01			1				
ommon effect model		25837		15305	<b>.</b>	1.046	[0.992; 1.103]	100.0%	
andom effects model						1.145	[0.952; 1.376]		100.0%
eterogeneity: $I^2 = 90\%$ , $\tau^2 = 0$	0.0736, p <	0.01			0.5 1 2				
est for subgroup differences (									
est for subgroup differences (r	random effe	$cts$ ): $\chi_1^2 = 0$	).12, df = 1	(p = 0.73)					

Subgroup analysis of age for the associations between overweight and obesity and the risk of constipation.

	Exper	imental		Control				Weight	Weight
Study	Events	Total	Events	Total	Risk Ratio	RR	95%-CI	(common)	(random)
Age = Children					8				
Teitelbaum JE 2009	37	122	114	483	<u>··</u>	1.285	[0.939; 1.757]	3.9%	8.0%
Koppen IJ 2016	71	542	270	2090		1.014	[0.795; 1.294]	6.5%	10.8%
Chang SH 2013	15	23	100	172		1.122	[0.811; 1.551]	3.7%	7.6%
Common effect model		687		2745	1.	1.112	[0.943; 1.312]	14.1%	
Random effects model					<u>+</u>	1.112	[0.943; 1.312]		26.3%
Heterogeneity: $I^2 = 0\%$ , $\tau^2 = 0$	, <i>p</i> = 0.50								
Age = Adult					i:				
Pourhoseingholi MA 2009	373	959	468	1158		0.962	[0.866; 1.070]	34.5%	19.6%
Hong Y 2024	347	4837	370	4026	—— <b>—</b> —	0.781	[0.678; 0.898]	19.6%	17.1%
Kudish BI 2009	427	5781	343	5028		1.083	[0.944; 1.242]	20.5%	17.4%
Talley NJ 2004	48	278	109	537		0.851	[0.626; 1.156]	4.1%	8.2%
Delgado-Aros S 2004	143	833	103	620		1.033	[0.820; 1.302]	7.2%	11.5%
Common effect model		12688		11369		0.944	[0.883; 1.009]	85.9%	
Random effects model						0.940	[0.827; 1.068]		73.7%
Heterogeneity: $I^2 = 67\%$ , $\tau^2 =$	0.0133, p = 1	0.02			i i				
Common effect model		13375		14114		0.966	[0.908; 1.028]	100.0%	
Random effects model						0.985	[0.884; 1.097]		100.0%
Heterogeneity: $I^2 = 58\%$ , $\tau^2 =$	0.0126. p = 1	0.02			0.75 1 1.5				
Test for subgroup differences			3.24, df = 1	(p = 0.07)					
Test for subgroup differences									
		, ,,,1							
JRE 5									
away wa awaly sia af a a c	foutlos	coociat	ions hot	NOOD OVOD	eight and the risk of constipation.				

random-effects model, but did not reveal any impact of adults on constipation risk (RR: 1.000; 95% CI: 0.786–1.303).

# 4 Discussion

Based on the pooled GWAS data, this study comprehensively analyzed the causal association of obesity with constipation. Both MR study and meta-analysis were carried out in this study to investigate the association between obesity and constipation risk. The use of bidirectional MR contributes to identifying high-risk populations and potential genetic targets, offering data support for personalized medicine and precision treatment. In combined treatments for obesity and constipation, MR analysis can identify specific genetic susceptibilities, promoting individualized interventions based on genetic characteristics. This innovative approach, grounded in causal inference, provides novel perspectives and directions for the prevention and management of obesity and constipation.

	Exper	imental		Control				Weight	Weigh
Study	Events	Total	Events	Total	Risk Ratio	RR	95%-CI	(common)	(random
Age = Children					1 :				
Feitelbaum JE 2009	45	152	114	483		1.254	[0.936; 1.681]	4.1%	9.8%
Koppen IJ 2016	28	188	270	2090		1.153	[0.805; 1.651]	2.7%	8.7%
Chang SH 2013	4	6	100	172	i i:	1.147	[0.642; 2.048]	1.0%	5.6%
'uwanita N 2018	18	31	31	119		- 2.229	[1.456; 3.411]	1.9%	7.6%
ashankar DS 2005	161	270	558	1379		1.474	[1.311; 1.657]	25.7%	12.5%
ehghani 2013	44	74	57	114	<u>'</u> *	1.189	[0.914; 1.547]	5.1%	10.3%
ommon effect model		721		4357		1.407	[1.282; 1.544]	40.6%	
andom effects model						1.370	[1.182; 1.589]		54.6%
Age = Adult			100			4 007		10 70	10.00
ourhoseingholi MA 2009	175	430	468	1158	;	1.007	[0.881; 1.151]	19.7%	12.39
long Y 2024	335	5185	370	4026		0.703	[0.610; 0.810]	17.5%	12.29
Kudish BI 2009	470	5602	343	5028		1.230	[1.076; 1.406]	19.7%	12.3%
alley NJ 2004	27	109	109	537		1.220	[0.845; 1.762]	2.6%	8.5%
common effect model		11326		10749	<b>*</b> !	0.976	[0.904; 1.054]	59.4%	
Random effects model leterogeneity: $I^2 = 91\%$ , $\tau^2 = 0$	0.0624, p < (	0.01				1.000	[0.768; 1.303]		45.4%
Common effect model		12047		15106		1.132	[1.067; 1.201]	100.0%	
Random effects model						1.186	[0.989; 1.420]		100.0%
Heterogeneity: $I^2 = 88\%$ , $\tau^2 = 0$	).0644. p < (	0.01			0.5 1 2				
est for subgroup differences (	common effe	ect): $\chi_1^2 = 3$							
105.6									
RE 6 group analysis of age									

As revealed by our results, BMI and WC showed causal associations with constipation. Various weight levels are associated with different health outcomes, which can be assessed by BMI. In this study, BMI was positively correlated with constipation. Constipation is more likely to occur with the increase in BMI. By contrast, BMI and constipation are non-linearly related, as found in the study by Xiang (7). In the study by Xiang (42), as BMI increases, constipation incidence initially decreases, while the risk rises significantly once BMI exceeds 28 kg/m<sup>2</sup>. WC is not associated with constipation in our study. To the best of our knowledge, only a few studies have examined the relationship between WC and constipation. Yurtdas (43) identified WC as a possible risk factor for constipation in women, which is consistent with our results, and higher WC was associated with a higher risk of constipation. We analyzed the causal effects of WHR and HC on constipation, finding no causal association. Constipation has been linked to overweight/obesity in many studies, but the results are inconsistent. Pawłowska revealed no significant difference in body weight/BMI between children with constipation and the control group (44). In addition, other studies showed that constipation was linked to underweight (45-47). The BMI and colonic transit time were negatively correlated in a study of 354 constipated patients (48).

To demonstrate the results of MR, we conducted a meta-analysis involving 14 observational studies (with 43,488 subjects), including six case–control, six cross-sectional, and two cohort studies. Obesity or overweight was found to be significantly related to constipation (RR: 1.145; 95% CI: 0.952–1.376). In the subgroup analysis, we divided the incidence of constipation in overweight or obese people into children and adults. It was found that overweight in adults would lower the risk of constipation, while obesity in adults exerted little effect on constipation. Being overweight or obese in children increases the risk of constipation. Several previous studies have reported that overweight/ obesity is one of the risk factors for constipation in children, while this is not entirely consistent with some current research findings (49). According to Pashankar et al. (36), children who were constipated had a greater prevalence of overweight/obesity. Compared with a healthy control group, Dehghani et al. (41) found that children with FC endured a significantly higher rate of obesity. It was indicated in another study that children with constipation are more likely to be overweight than those in the control group (50). In contrast, some studies found that children with chronic constipation were more likely to be underweight and to grow at a slower rate (45, 46, 51). In addition, early diagnosis and treatment of constipation could facilitate the growth of a child.

The study by Moayyedi (52) proposed that the increased risk of constipation in obese people might be directly related to their food intake off and that the excessive food intake causes the stomach to expand rapidly, transporting food to the small intestine. The volume increases, resulting in an increased osmotic load and subsequent delivery of more to the colon stool, and stool consistency increases, which leads to constipation. Direct endocrine effects of adipokine may also affect the movement of the gastrointestinal tract. Rajindrajith et al. (53) also reported that rapid gastric emptying and intestinal or colon rotation in obese children reduced transit time and altered secretory response might partly explain the relationship between constipation and obesity. In addition, overweight/obese children are more often associated with unhealthy drinking, eating habits, and lifestyle, as well as excessive intake of high-fat foods. In addition, too little high-fiber food intake and lack of exercise have a certain effect on the occurrence of constipation. Another possible mechanism is probably related to brain-gut neuropeptides, among which, neuropeptides including ghrelin, leptin, glucagon-like peptide-1, and cholecystokinin are vital for satiety, hunger, and gastrointestinal motility. Gastrointestinal neuropeptides (like ghrelin) are demonstrated to promote small intestinal and colonic transit and exert potent prokinetic function. Ghrelin level is reported to increase in normal-weighted individuals when compared with obese people (54).

Psychosocial diseases have been suggested to exert critical effects on the pathophysiology of obesity and constipation. In some studies, obese children usually develop psychosocial disorders, including anxiety, depression, or lack of self-esteem (54, 55). Such disorders are probably associated with early-life alterations in gut microbiota, like compositional alterations, therefore indicating the occurrence and maintenance of constipation (56, 57). Additionally, it is a critical factor for energy metabolism and obesity occurrence (58-60). Devkota et al. reported that dietary fat dramatically reorganized intestinal microbiota in animal models, causing ecological diseases and disturbing immune homeostasis (61). Similarly, obesity is related to microbial alterations, decreased bacterial diversity, and changed metabolic pathways (58). Therefore, overweight/obesity may lead to a higher constipation risk among children through several mechanisms. Our results are consistent with the results of Eslick's (62) systematic review that obesity is not associated with the risk of adult constipation. In our study, obesity was considered to cause constipation, but constipation did not cause obesity. Consequently, more investigations are needed to explore the potential mechanisms and shed more light on their interactions in the pathogenesis of both diseases.

# 5 Strengths and limitations

There are some strengths in this study. First, this study mainly concentrated on population-based studies on obesity with a large study population (n = 43,488), providing complete and creditable findings in comparison with prior meta-analysis results. Second, studies were classified based on age and obesity degree; in addition, factors were adjusted, and their influence on the association of exposure with outcome was estimated. Third, this is the first MR analysis that evaluates the causal association of obesity with constipation. Moreover, the study design was in strict accordance with the MR assumptions (63), avoiding the impacts of possible confounders and reverse causality. This revealed an independent association of obesity with constipation. Fourthly, obesity-related and constipation-related SNPs were obtained from the currently most complete GWAS, contributing to explaining the genetic association of obesity with constipation and providing accurate estimates. Based on our knowledge, this is the first study examining the reciprocal causal association of obesity with constipation by MR methods. In addition, the genetic summary data in obese subjects were obtained from the Cochrane Library, Web of Science, PubMed, and Embase databases from inception to 1 February 2024, enhancing the statistical power for evaluating the causality.

Nevertheless, there are certain limitations in this study. At first, due to the restricted number of publications, the subjects enrolled for metaanalysis were mostly Asians and Caucasians, while summary data for the MR study were obtained from subjects of European descent. Consequently, more research is warranted to generalize the results to additional populations. In addition, because of the restricted source of IVs regarding obesity, we did not stratify the study population by confounders such as sex, drug use, and disease course, which inevitably induced possible bias resulting from these confounders. However, eliminating all types of confounding factors can bring a great challenge. In the future, we will use multiple omics or wet experiments to reveal the interaction between obesity and constipation.

# 6 Conclusion

Collectively, obese people are associated with an increased risk of constipation, and genetically predisposed obesity shows a causal association with a higher constipation risk. However, constipation does not exhibit any causal association with a higher obesity risk. More studies are needed to explore the contributing mechanism of obesity to constipation. In addition, our study suggests that we can develop interventions for constipation from the perspective of obesity. In addition, some people with chronic constipation may be able to relieve their constipation by controlling their weight.

# Author contributions

XS: Data curation, Writing – review & editing. SZ: Data curation, Writing – review & editing. XZ: Conceptualization, Formal Analysis, Writing – original draft.

# Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The study was financially supported by the National Nature Science Foundation of China (82405394).

# Acknowledgments

The authors gratefully acknowledge the data obtained from the genome-wide association studies (GWAS).

# Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

# Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2024.1430280/ full#supplementary-material

#### 10.3389/fnut.2024.1430280

# References

1. Markland AD, Palsson O, Goode PS, Burgio KL, Busby-Whitehead J, Whitehead WE. Association of low dietary intake of fiber and liquids with constipation: evidence from the national health and nutrition examination survey. *Am J Gastroenterol.* (2013) 108:796–803. doi: 10.1038/ajg.2013.73

2. Belsey J, Greenfield S, Candy D, Geraint M. Systematic review: impact of constipation on quality of life in adults and children. *Aliment Pharmacol Ther.* (2010) 31:938–49. doi: 10.1111/j.1365-2036.2010.04273.x

3. Heidelbaugh JJ, Stelwagon M, Miller SA, Shea EP, Chey WD. The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: us survey assessing symptoms, care seeking, and disease burden. *Am J Gastroenterol.* (2015) 110:580–7. doi: 10.1038/ajg.2015.67

4. Martin BC, Barghout V, Cerulli A. Direct medical costs of constipation in the United States. *Manag Care Interface*. (2006) 19:43–9.

5. Yurtdas G, Acar-Tek N, Akbulut G, Cemali O, Arslan N, Beyaz CA, et al. Risk factors for constipation in adults: a cross-sectional study. J Am Coll Nutr. (2020) 39:713–9. doi: 10.1080/07315724.2020.1727380

6. Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, et al. Health effects of overweight and obesity in 195 countries over 25 years. *N Engl J Med.* (2017) 377:13–27. doi: 10.1056/NEJMoa1614362

7. Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C, et al. Projected u.s. state-level prevalence of adult obesity and severe obesity. *N Engl J Med.* (2019) 381:2440–50. doi: 10.1056/NEJMsa1909301

8. Aune D, Norat T, Vatten LJ. Body mass index, abdominal fatness and the risk of gallbladder disease. *Eur J Epidemiol*. (2015) 30:1009–19. doi: 10.1007/s10654-015-0081-y

9. Milic S, Lulic D, Stimac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. *World J Gastroenterol.* (2014) 20:9330–7. doi: 10.3748/wjg.v20.i28.9330

10. Koppen IJ, Velasco-Benitez CA, Benninga MA, Di Lorenzo C, Saps M. Is there an association between functional constipation and excessive bodyweight in children? *J Pediatr.* (2016) 171:178–182.e1. doi: 10.1016/j.jpeds.2015.12.033

11. Pourhoseingholi MA, Kaboli SA, Pourhoseingholi A, Moghimi-Dehkordi B, Safaee A, Mansoori BK, et al. Obesity and functional constipation; a community-based study in Iran. *J Gastrointestin Liver Dis.* (2009) 18:151–5.

12. Costa ML, Oliveira JN, Tahan S, Morais MB. Overweight and constipation in adolescents. *BMC Gastroenterol.* (2011) 11:40. doi: 10.1186/1471-230X-11-40

13. Davies NM, Holmes MV, Davey SG. Reading mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ.* (2018) 362:k601. doi: 10.1136/ bmj.k601

14. Barlow SE. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. *Pediatrics*. (2007) 120:S164–92. doi: 10.1542/peds.2007-2329C

15. Jiang L, Zheng Z, Fang H, Yang J. A generalized linear mixed model association tool for biobank-scale data. *Nat Genet.* (2021) 53:1616–21. doi: 10.1038/ s41588-021-00954-4

16. Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. *JAMA*. (2017) 318:1925–6. doi: 10.1001/jama.2017.17219

17. Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023. *Wellcome Open Res.* (2023) 4:186. doi: 10.12688/wellcomeopenres.15555.3

18. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol.* (2013) 37:658–65. doi: 10.1002/gepi.21758

19. Zhou H, Zhu H, Wang J, Gao X, Jiang C. Association between hypothyroidism subtypes and major depression: a two-sample Mendelian randomization study. *J Affect Disord*. (2024) 351:843–52. doi: 10.1016/j.jad.2024.02.006

20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. (2003) 327:557–60. doi: 10.1136/bmj.327.7414.557

21. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol.* (2010) 25:603–5. doi: 10.1007/s10654-010-9491-z

22. Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. *J Evid Med.* (2015) 8:2–10. doi: 10.1111/jebm.12141

23. Hu J, Dong Y, Chen X, Liu Y, Ma D, Liu X, et al. Prevalence of suicide attempts among chinese adolescents: a meta-analysis of cross-sectional studies. *Compr Psychiatry*. (2015) 61:78–89. doi: 10.1016/j.comppsych.2015.05.001

24. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. (1986) 7:177–88. doi: 10.1016/0197-2456(86)90046-2

25. Zheng JS, Hu XJ, Zhao YM, Yang J, Li D. Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: meta-analysis of data from 21 independent prospective cohort studies. *BMJ*. (2013) 346:f3706. doi: 10.1136/bmj.f3706

26. Wu QJ, Yang G, Zheng W, Li HL, Gao J, Wang J, et al. Pre-diagnostic cruciferous vegetables intake and lung cancer survival among chinese women. *Sci Rep.* (2015) 5:10306. doi: 10.1038/srep10306

27. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med.* (2002) 21:1539–58. doi: 10.1002/sim.1186

28. Jin M, Cai S, Guo J, Zhu Y, Li M, Yu Y, et al. Alcohol drinking and all cancer mortality: a meta-analysis. *Ann Oncol.* (2013) 24:807–16. doi: 10.1093/annonc/mds508

29. Papageorgiou SN, Papadopoulos MA, Athanasiou AE. Assessing small study effects and publication bias in orthodontic meta-analyses: a meta-epidemiological study. *Clin Oral Investig.* (2014) 18:1031–44. doi: 10.1007/s00784-014-1196-3

30. He Y, Karhunen V, Pulakka A, Kantomaa M, Sebert S. A bidirectional mendelian randomisation study to evaluate the relationship between body constitution and hearing loss. *Sci Rep.* (2023) 13:18434. doi: 10.1038/s41598-023-44735-x

31. Teitelbaum JE, Sinha P, Micale M, Yeung S, Jaeger J. Obesity is related to multiple functional abdominal diseases. *J Pediatr.* (2009) 154:444–6. doi: 10.1016/j. jpeds.2008.09.053

32. Olaru C, Diaconescu S, Trandafir L, Gimiga N, Stefanescu G, Ciubotariu G, et al. Some risk factors of chronic functional constipation identified in a pediatric population sample from Romania. *Gastroenterol Res Pract.* (2016) 2016:3989721. doi: 10.1155/2016/3989721

33. Chang SH, Park KY, Kang SK, Kang KS, Na SY, Yang HR, et al. Prevalence, clinical characteristics, and management of functional constipation at pediatric gastroenterology clinics. *J Korean Med Sci.* (2013) 28:1356–61. doi: 10.3346/jkms.2013.28.9.1356

34. Natasha Y, Atan BS, Tiangsa S, Supriatmo S, Ade RY. Obesity and functional constipation in children. *Paediatr Indones*. (2018) 58:1. doi: 10.14238/pi58.1.2018.1-4

35. Phatak UP, Pashankar DS. Prevalence of functional gastrointestinal disorders in obese and overweight children. Int J Obes. (2014) 38:1324–7. doi: 10.1038/ijo.2014.67

36. Pashankar DS, Loening-Baucke V. Increased prevalence of obesity in children with functional constipation evaluated in an academic medical center. *Pediatrics*. (2005) 116:e377–80. doi: 10.1542/peds.2005-0490

37. Hong Y, Chen X, Liu J. Analysis of factors associated with constipation in the population with obesity: evidence from the national health and nutrition examination survey. *Obes Facts.* (2024) 17:169–82. doi: 10.1159/000536318

38. Kudish BI, Iglesia CB, Sokol RJ, Cochrane B, Richter HE, Larson J, et al. Effect of weight change on natural history of pelvic organ prolapse. *Obstet Gynecol.* (2009) 113:81–8. doi: 10.1097/AOG.0b013e318190a0dd

39. Talley NJ, Howell S, Poulton R. Obesity and chronic gastrointestinal tract symptoms in young adults: a birth cohort study. *Am J Gastroenterol.* (2004) 99:1807–14. doi: 10.1111/j.1572-0241.2004.30388.x

40. Delgado-Aros S, Locke GR, Camilleri M, Talley NJ, Fett S, Zinsmeister AR, et al. Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. *Am J Gastroenterol.* (2004) 99:1801–6. doi: 10.1111/j.1572-0241.2004.30887.x

41. Dehghani SM, Karamifar H, Imanieh MH, Mohebbi E, Malekpour A, Haghighat M. Evaluation of the growth parameters in children with chronic functional constipation. *Ann Colorect Res.* (2013) 1:54–8. doi: 10.17795/acr-11979

42. Xiang N, Xu L, Qian H, Zhang D. Multiple obesity indices suggest a close relationship between obesity and constipation: evidence from NHANES. *BMC Public Health*. (2024) 24:1273. doi: 10.1186/s12889-024-18647-y

43. Yurtdas G, Akbulut G, Acar Tek N. The relationship between waist circumference and dietary intake and functional constipation in women. *Clin Nutr.* (2019) 38:S114–5. doi: 10.1016/S0261-5614(19)32782-7

44. Pawłowska K, Umławska W, Iwańczak B. A link between nutritional and growth states in pediatric patients with functional gastrointestinal disorders. *J Pediatr.* (2018) 199:171–7. doi: 10.1016/j.jpeds.2018.02.069

45. Chao H-C, Chen S-Y, Chen C-C, Chang K-W, Kong M-S, Lai MW, et al. The impact of constipation on growth in children. *Pediatr Res.* (2008) 64:308–11. doi: 10.1203/PDR.0b013e31817995aa

46. Santucci NR, Hyman PE. Do functional gastrointestinal disorders affect growth and nutrition? *J Pediatr.* (2018) 199:9–10. doi: 10.1016/j.jpeds.2018.04.006

47. Squires JE, Alonso EM, Ibrahim SH, Kasper V, Kehar M, Martinez M, et al. North American Society for Pediatric Gastroenterology, hepatology, and nutrition position paper on the diagnosis and Management of Pediatric Acute Liver Failure. *J Pediatr Gastroenterol Nutr.* (2022) 74:138–58. doi: 10.1097/MPG.000000000003268

48. Bouchoucha M, Fysekidis M, Rompteaux P, Airinei G, Sabate JM, Benamouzig R. Influence of age and body mass index on Total and segmental colonic transit times in constipated subjects. *J Neurogastroenterol Motil.* (2019) 25:258–66. doi: 10.5056/jnn18167

49. Misra S, Liaw A. Controversies on the relationship between increased body mass index and treatment-resistant chronic constipation in children. *JPEN J Parenter Enteral Nutr.* (2022) 46:1031–5. doi: 10.1002/jpen.2300

50. Misra S, Lee A, Gensel K. Chronic constipation in overweight children. JPEN J Parenter Enteral Nutr. (2006) 30:81–4. doi: 10.1177/014860710603000281

51. North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. Evaluation and treatment of constipation in children: summary of updated recommendations of the north American Society for Pediatric Gastroenterology, hepatology and nutrition. *J Pediatr Gastroenterol Nutr.* (2006) 43:405–7. doi: 10.1097/01. mpg.0000232574.41149.0a

52. Moayyedi P. The epidemiology of obesity and gastrointestinal and other diseases: an overview. *Dig Dis Sci.* (2008) 53:2293–9. doi: 10.1007/s10620-008-0410-z

53. Rajindrajith S, Devanarayana NM, Benninga MA. Obesity and functional gastrointestinal diseases in children. *J Neurogastroenterol Motil.* (2014) 20:414–6. doi: 10.5056/jnm14067

54. Schwimmer JB, Burwinkle TM, Varni JW. Health-related quality of life of severely obese children and adolescents. *JAMA*. (2003) 289:1813–9. doi: 10.1001/jama.289.14.1813

55. Russell-Mayhew S, McVey G, Bardick A, Ireland A. Mental health, wellness, and childhood overweight/obesity. J Obes. (2012) 2012:281801. doi: 10.1155/2012/281801

56. Mayer EA, Savidge T, Shulman RJ. Brain-gut microbiome interactions and functional bowel disorders. *Gastroenterology*. (2014) 146:1500–12. doi: 10.1053/j. gastro.2014.02.037

57. Zhu L, Liu W, Alkhouri R, Baker RD, Bard JE, Quigley EM, et al. Structural changes in the gut microbiome of constipated patients. *Physiol Genomics*. (2014) 46:679–86. doi: 10.1152/physiolgenomics.00082.2014

58. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. *Nature*. (2009) 457:480–4. doi: 10.1038/ nature07540

59. Kalliomäki M, Collado MC, Salminen S, Isolauri E. Early differences in fecal microbiota composition in children may predict overweight. *Am J Clin Nutr.* (2008) 87:534–8. doi: 10.1093/ajcn/87.3.534

60. Tilg H, Adolph TE. Influence of the human intestinal microbiome on obesity and metabolic dysfunction. *Curr Opin Pediatr.* (2015) 27:496–501. doi: 10.1097/MOP.0000000000234

61. Devkota S, Wang Y, Musch MW, Leone V, Fehlner-Peach H, Nadimpalli A, et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in ll10–/– mice. Nature. (2012) 487:104–8. doi: 10.1038/nature11225

62. Eslick GD. Gastrointestinal symptoms and obesity: a meta-analysis. Obes Rev. (2012) 13:469–79. doi: 10.1111/j.1467-789X.2011.00969.x

63. VanderWeele TJ, Tchetgen TE, Cornelis M, Kraft P. Methodological challenges in mendelian randomization. *Epidemiology*. (2014) 25:427–35. doi: 10.1097/EDE.00000000000081